Profusa (PFSA) Net Income towards Common Stockholders (2022 - 2026)
Profusa (PFSA) reported Net Income towards Common Stockholders of -$4.0 million for Q1 2026, down 259.31% on a YoY basis from $2.5 million in Q1 2025, and up 13.43% quarter-over-quarter from -$4.6 million in Q4 2025.
Profusa (PFSA) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Profusa has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 259.31% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$38.7 million (down 329.33% YoY), and the FY2025 full-year result was -$30.2 million, down 246.43% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$4.0 million, up from -$4.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $2.9 million in Q1 2022, with the low at -$21.9 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$2.7 million across 5 years, with a median of -$397487.0 in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 129.48% — and 2025, when it slumped 24095.09%.
- Profusa's Net Income towards Common Stockholders stood at -$3.7 million in 2022, then jumped by 105.74% to $212692.0 in 2023, then plunged by 3672.63% to -$7.6 million in 2024, then surged by 38.83% to -$4.6 million in 2025, then advanced by 13.43% to -$4.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.0 million (Q1 2026), -$4.6 million (Q4 2025), and -$21.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Profusa | 1.59 Mn | 1.59 Mn | - | -4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.02 Mn |
| Dec 31, 2025 | -4.65 Mn |
| Sep 30, 2025 | -21.88 Mn |
| Jun 30, 2025 | -8.20 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -7.60 Mn |
| Sep 30, 2024 | 91,177.00 |
| Jun 30, 2024 | -397,487.00 |
| Mar 31, 2024 | -820,277.00 |
| Dec 31, 2023 | 212,692.00 |
| Sep 30, 2023 | -309,328.00 |
| Jun 30, 2023 | 134,623.00 |
| Mar 31, 2023 | 336,660.00 |
| Dec 31, 2022 | -3.71 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 951,832.00 |
| Mar 31, 2022 | 2.91 Mn |